Natco Pharma LimitedQ1 FY27 Results & Financial Update
Natco Pharma Limited: Q1 FY27 consolidated results and company financials – revenue ₹735.20 Cr, PAT ₹206.50 Cr. Explore reported YoY/QoQ movements, margins, business drivers and management commentary. This page does not provide a rating, target price or investment recommendation.
Quarter at a glanceCurrent reported figures.Change figures appear when a comparable reported period is available.
Find an answer
Ask this result
Chart · Market context
Natco Pharma price & chart
Market priceLoading…
1Y return—Price return
Loading market chart…
TradingView Lightweight Charts™ · Copyright © 2025 TradingView, Inc.TradingView
Market chartPrice chart temporarily unavailableThe price chart could not be loaded right now. The reported financial results remain available above.
Spotted a factual error?Tell us the number, date or statement and we will re-check the underlying records and calculations.Report an error
Quarterly Results AnalysisExplore Natco Pharma Q1 FY27 quarterly results and earnings: revenue, profit (PAT), EBITDA, margins, YoY and QoQ growth, order book or business updates where reported, financial performance and management commentary. Reported figures and Nivata calculations are shown separately; no buy, sell or hold recommendation is provided.
Quarter overview
Quarterly earnings analysis
Natco Pharma Limited released its unaudited consolidated financial results for the first quarter of fiscal year 2027 (ended 30 June 2026), reporting revenue from operations of INR 735.20 crore.
Total income for the quarter stood at INR 794.40 crore, supported by other income of INR 59.20 crore which contributed to overall revenue generation during the period.
Profit before tax (PBT) for Q1 FY27 was recorded at INR 185.60 crore, reflecting the company's operational performance after accounting for finance costs of INR 13.00 crore and depreciation and amortization expenses of INR 47.10 crore.
The company reported a net profit (PAT) of INR 206.50 crore for the quarter, resulting in a basic and diluted earnings per share (EPS) of INR 11.53.
Tax expense for the period stood at INR 63.40 crore, shaping the net earnings profile alongside the pre-tax performance.
Alongside the financial results, the Board of Directors declared an interim dividend of INR 1.50 per equity share (75% on a face value of INR 2.00 each) for the financial year ending 31 March 2027, with the record date set for 20 August 2026 and payment commencing from 26 August 2026.
Natco Pharma Limited reported its un-audited consolidated financial results for the first quarter of fiscal year 2027, covering the period ended June 30, 2026, showcasing steady operational income and profitability.
During the quarter, the company generated revenue from operations of INR 735.2 crore, alongside other income of INR 59.2 crore, bringing total consolidated income to INR 794.4 crore.
01 · Business model
What does Natco Pharma do?
Natco Pharma Limited is an Indian pharmaceutical company headquartered in Hyderabad, Telangana, engaged in the development, manufacture, and commercialization of complex finished dosage formulations and active pharmaceutical ingredients (APIs).
The company operates on a global scale with a strong emphasis on niche therapeutic segments, particularly oncology, specialty pharmaceuticals, and complex generic drugs catering to regulated and emerging international markets.
Natco's revenue engine is driven by high-barrier generic product launches in key regulated geographies like the United States, alongside a robust domestic portfolio spanning oncology, gastroenterology, and critical care therapies.
The operational model relies on research-led development of challenging molecules, strategic marketing partnerships in overseas markets, and specialized manufacturing facilities designed to meet stringent global regulatory standards.
02 · Financial snapshot
Current-quarter financial snapshot
| Metric | Q1 FY27 |
|---|---|
| Revenue from operations | ₹735.20 Cr |
| Total income | ₹794.40 Cr |
| Profit before tax | ₹185.60 Cr |
| Profit after tax | ₹206.50 Cr |
| EPS | ₹11.53 |
Financial interpretation
What the reported numbers mean
Profit after tax represented 28.1% of reported quarterly operating revenue. This is a calculated net-profit-to-sales ratio, not a company-reported operating margin. It measures the outcome after expenses and tax; it does not, by itself, establish how margins changed versus another period.
Profit before tax was equivalent to 25.2% of quarterly operating revenue. The distinction between pre-tax and post-tax profit matters when interpreting earnings; neither ratio identifies an underlying cost driver without a properly matched comparative period.
Total income exceeded operating revenue by ₹59.20 crore. This is the disclosed difference between the two lines, not incremental sales. The distinction matters when assessing how much of the quarter’s reported income came from the operating top line.
Ratios above are calculated from the reported quarterly figures. They are analytical descriptions, not company-reported margin guidance or an investment recommendation.
03 · Why it moved
Why the quarter looked the way it did
What drove revenue
The company generated INR 735.20 crore in revenue from operations for the quarter ended 30 June 2026.
Other income added INR 59.20 crore to the financial results, lifting total income to INR 794.40 crore for Q1 FY27.
The company recorded consolidated revenue from operations of INR 735.2 crore for the quarter ended June 30, 2026.
Total income reached INR 794.4 crore, supported by INR 59.2 crore of other income streams during the quarter.
What drove margins
The company absorbed INR 47.10 crore in depreciation and amortization expenses and INR 13.00 crore in finance costs during the quarter.
Tax expenses for the quarter were recorded at INR 63.40 crore, influencing the net profit margin standing at 28.09% of total income.
04 · Reported developments
What changed operationally
The Board of Directors declared an interim dividend of INR 1.50 per equity share (75%) for the financial year ending 2027.
The board of directors declared an interim dividend of INR 1.50 per equity share (75% of face value) for the financial year 2026-27.
05 · Beyond the numbers
What changed beyond the numbers
Reported update
Interim Dividend Schedule
The record date for the interim dividend of INR 1.50 per share is 20 August 2026, with payouts scheduled to start on 26 August 2026.
Reported update
Dividend Payout Schedule
Payment of the declared interim dividend is set to begin on or after August 26, 2026.
06 · Key Q&A
The quarter, answered directly
What does Natco Pharma do?
Natco Pharma Limited is an Indian pharmaceutical company headquartered in Hyderabad, Telangana, engaged in the development, manufacture, and commercialization of complex finished dosage formulations and active pharmaceutical ingredients (APIs).
What is the clearest takeaway from Q1 FY27?
Natco Pharma Limited released its unaudited consolidated financial results for the first quarter of fiscal year 2027 (ended 30 June 2026), reporting revenue from operations of INR 735.20 crore.
What drove revenue or demand?
The company generated INR 735.20 crore in revenue from operations for the quarter ended 30 June 2026.
What mattered most for margins or profitability?
The company absorbed INR 47.10 crore in depreciation and amortization expenses and INR 13.00 crore in finance costs during the quarter.
What changed operationally beyond the headline numbers?
The record date for the interim dividend of INR 1.50 per share is 20 August 2026, with payouts scheduled to start on 26 August 2026.
What should the next disclosure help confirm?
Track upcoming quarterly financial disclosures for subsequent periods of FY27 to evaluate sequential operational progress.
07 · Scenario calculator
Earnings sensitivity: what if growth and margins change?
Starting point
Build your own next-quarter scenario
Reported values are prefilled where a comparable basis is available. Otherwise, the field starts at 0. You can overwrite every field.
Example: enter 10 for 10% revenue growth. Enter -100 for a 1 percentage-point margin decline.
Scenario output
Scenario revenue / income₹0 cr
Scenario profit after tax₹0 cr
Profit change vs base₹0 cr (0%)
Scenario margin0%
Growth needed to keep profit flat after this margin move0%
The calculator holds the selected margin basis constant except for the basis-point adjustment you enter. It does not estimate tax, finance cost, dilution, working capital, valuation or share price.
08 · Next filing checkpoints
What the next disclosure can confirm or change
- 01
Subsequent Quarter Financial Disclosures: Track upcoming quarterly financial disclosures for subsequent periods of FY27 to evaluate sequential operational progress.
- 02
Dividend Distribution: Monitor the commencement of interim dividend payouts scheduled from August 26, 2026.
Learn the metrics
Need the concepts first?
Use Nivata’s plain-English guides to understand the accounting terms used in this brief before interpreting them.